Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Researchers advance non-invasive cancer detection methods
Researchers at Vilnius University have developed an effective approach to liquid biopsy that contributes to the field of ...
Cure Today3d
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...
Cure Today4d
mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer
Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...
UroToday6d
ASCO GU 2025: Beneath the Surface: Unleashing the Potential of ctDNA across the Spectrum of Urothelial Carcinoma
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Panning for Gold: The Role of ctDNA as ...